FindTrial
Sign In

MINT

A Phase 2, Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of AZD8931 In Combination With Anastrozole, Compared to Anastrozole Alone, in Post Menopausal Women With Hormone Receptor Positive, Endocrine Therapy Naive, Locally Advanced or Metastatic Breast Cancer

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221559
Enrollment
Unknown
Registered
2011-09-02
Start date
2011-09-02
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasms, Breast Neoplasms, Breast Cancer

Interventions

investigational material(s) Generic name etc : AZD8931, Anastrozole INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigatio

Sponsors

AstraZeneca
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: - Patients that have locally advanced or metastatic breast cancer. Lesions should not be amenable to surgery or radiation of curative intent - Hormone therapy-naive - Estimated life expectancy of more than 12 weeks

Exclusion criteria

Exclusion criteria: - Last dose of prior anti-cancer therapy received within 14 days (or longer if required) - Any eye injury or corneal surgery within 3 months prior to receiving first dose of study drug. - Currently receiving (and unwilling to discontinue) oestrogen replacement therapy. (last dose <7 days prior to randomisation)

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026